medigraphic.com
ISSN 2007-3194 (Print)
Órgano de difusión oficial del Instituto Materno Infantil del Estado de México

2011, Number 3

<< Back Next >>

Arch Inv Mat Inf 2011; 3 (3)

Frecuencia y curso clínico de candidiasis neonatal

Demesa AR, Valdés LA, García RJF

Language: Spanish
References: 36
Page: 121-127
PDF size: 93.18 Kb.


ABSTRACT

Introduction: A dramatic increase in the incidence of fungal infections has been reported in recent years. This especially true with mortality include age, invasive procedures and previous use of antibiotics. Systemic Candidiasis constitutes an important cause of morbimortality in newborns in Intensive Care Units. Material and methods: Retrospectively we reviewed 40 case histories of newborns in the Neonatal Intensive Care Unit of the Hospital of Children IMIEM from January 2004 to January 2009, with an release or death diagnosis of Systemic Candidiasis, based on positive cultures in one or more site or corporal fluids. The objective was to analyze the factors associated to Candidiasis. The information was obtained from the archives of Hospital of Children. The individual patient record was carefully reviewed in efforts to determine possible risk factors at the time of the positive cultures as well as the antecedent of Candidiasis. Results: We observed 40 infectious events due to Candida spp, with a mortality of 38%; the age group with the highest mortality was newborns preterminy 55%. The broad spectrum antibiotics use predominated (90%) between the associated risk factors. The main factors associated with mortality were the antecedent as well as being intubated at the moment of the infection. Conclusions: Fungal infections and particularly those due to Candida spp, represent an important cause of morbidity and mortality. The broad spectrum antibiotic use predominated between the associated risk factors. The associated risk factors are those due to protracted use of broad spectrum antibiotics and invasive procedures including endotracheal intubation. An increase in the isolation of Candida was noted.


REFERENCES

  1. American Academy of Pediatrics, Candidiasis. En: Peter G ed. Red Book, 25 editions, Elk Grove Village 2000: 198-201.

  2. Hostetter MK, Candida species, In: Long SS, Pickering LK, Prober CG. Principles and practice pediatric, Infectious Disease Churchill Livingston, 1era Ed. Nueva York, 1997: 1313-1326.

  3. Hughes WT, Flynn PM. Candidiasis, In: Feigin RD, Cherry JD. Textbook of pediatric infectous diseases, Saunders Company 4a Ed. Philadelphia, 1998: 2303-2313.

  4. Godoy P, Tiraboshi I, Severo C, Bustamante B, Calvo B, De Almeida L et al. Species distribution an antifungal susceptibility profile of Candida spp bloodstream isolates from Latin America hospitals, Mem Inst 2003; 98: 401-404.

  5. Vargas OA. Candidiasis neonatal. Boletín Médico Hospital Infantil de México 2003; 60: 543-555.

  6. Macola S. Candida. En: Llop A, Valdés-Dapeno M, Zuazo JL. Microbiología y parasitología médicas, Habana: Editorial Ciencias Médicas 2001; I: 501-7.

  7. Pfaller MA. Nosocomial candidiasis; emerging species, reservoir an modes of transmition, Clin Infect Dis 1996; 22 (Suppl 2): 89-94.

  8. Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infection, Clin Microbiol Rev 1996; 9: 499-511.

  9. MacDonald L, Baker C, Chenoweth C. Risk factors for candidemia in a Children ‘Hospital, Clin Infect Dis 1998; 26: 642-5.

  10. Jarvis WR. Epidemiology of nosocomial fungal infections with emphasis on Candida species, Clin Infect Dis 1995; 20: 1526-30.

  11. Stamos JK, Roelwy AH. Candidemia in a pediatric population, Clin Infect Dis 1995; 20: 571-5.

  12. Saiman L, Ludington E, Pfaller M, Rangel-Frausto S, Wiblin T, Dawson J et al. Risk factors for candidemia in Neonatal Intensive Care Unit patients, Pediatric Infect Dis J 2000; 19: 319.

  13. Baley JE. Neonatal candidiasis the current challenger, Clin Perinatol 1991; 18: 263.

  14. Coleman DC, Rinaldi MG, Haynes KA, Importance of Candida species other than Candida albicans, Med Mycol 1998; 36 (Suppl 1): S156-65.

  15. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections, 1980-1990. National Nosocomial Infection Surveillance System, Journal of Infectious Diseases 1993; 167: 1247-51.

  16. Stoll BJ, Hansen N, Fanaroff AA, Writh LL, Carlo WA, Ehrenkraz RA et al. Late–onset sepsis in very low birth weight neonates: the experience on the neonatal research network, Pediatrics 2002; 110: 285-91.

  17. Lupetti A, Tavanti A, Davini P, Ghelardi, Corsini V, Meusi I et al. Horizontal transmission of Candida in a Neonatal Intensive Care Unit, Journal of Clinical Microbiology 2002; 40: 2363-9.

  18. Miller ME. Host defenses in the neonate. New York, Grune and Stratton 1999: 2-18.

  19. Bendel CCM, Hostetter MK. Systemic candidiasis and other fungal infection in the newborn, Seminars in Pediatrics Infectious Diseases 1994; 5: 35.

  20. McGinnis MR, Tilton RC. Yeasts. In: Howard BJ, Keiser JF, Smith TF, Weissfeld M, Tilton CR. Clinical and pathogenic microbiology, 2nd Ed. St Louis: Mosby, 1994: 615-24.

  21. Murray PR, Rosenthal KS, Kabayashi GS, Pfaller MA, Medical microbiology, 4th Ed. St Louis: Mosby. 2002.

  22. Satre LJ, Coto CG, Fernández CB et al. Neonatal invasive candidiasis: a prospective multicenter study of 118 cases, Am J Perinatology 2003; 20 (3): 153-163.

  23. Isaacs D. Richard E. Fungi infections. ErNeoanatal infections Oxford Butterworth, Heinemann 1991: 140-148.

  24. Eppes SC, Trotman JL, Gutman LT. Outcome of treatment of candidemia in children whose central catheter were removed or retained, Pediatr Infect Dis J 1989; 8: 99.

  25. Weese MDE, Fondriest DW, Brouillete RT et al. Risk factors associated with candidemia in the Neonatal Intensive Care Unit case-control study, Pediatr Infect Dis 1987: 6-190.

  26. Leibovitz E, Luster R et al. Systemic Candida infections associated with use of peripheral venous catheter in neonates: a 9 years experience, Clin Infect Dis 1992; 14: 485.

  27. Gilmore BJ, Retsinas EM, Lorenz JS et al. An iC3b receptor on Candida albicans: Structures function and correlates for pathogenicity, J Infect Dis 1998; 157: 3b.

  28. Fah S, Wong B. Current status of non culture methods for diagnosis of invasive fungal infections, Clinical Microbiology Review 2002; 15: 465-84.

  29. Difonzo EM, Terragni L. El laboratorio en las micosis superficiales, Barcelona: Publicidad Permanyer, 1990.

  30. Rinaldi MG, Haynes KA. Candida species other than Candida albicans, Med Mycol 1998; 36 (Suppl 1): S156-65.

  31. Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, Edwards JE. Practice guidelines for the treatment of candidiasis, Clinical Infectious Diseases 2000; 30: 662-78.

  32. Moragues MD, Omaetxebarria MJ, Elguezabal N, Bikandi J, Quindós G. Serological differentiation of experimentally induced Candida dubliniensis and Candida albicans infections, Journal Clinical Microbiology 2001; 39: 2999-3001.

  33. Bikandi J, Millán R, Regúlez P, Moragues MD, Quindós G, Pontón J. Detection of antibodies to Candida albicans germ tubes during experimental infections by different Candida species, Clinical and Diagnostic Laboratory Immunology 1998; 5: 369-74.

  34. Kondori N, Edebo L, Mattsby-Baltzer I. Circulating b (1-3) glucan and immunoglobulin G subclass antibodies to Candida albicans cell wall antigens in patients with systemic candidiasis, Clinical Diagnostic Laboratory Immunology 2004; 11: 344-50.

  35. Napoleón GS, Saltigeral SP. Antimicóticos. Guía de Antimicrobianos, antivirales, antiparasitarios, antimicóticos e inmunomoduladores. Nieto Editores, Octava Edición, 2008: 277-278.

  36. Carol K, Taketomo JH, Hodding DM, Kraus. Manual de prescripción pediátrica. Fluconazol. Intersistemas Editores, 10ª Edición, 2004: 473-475.




2020     |     www.medigraphic.com